Survival analysis revealed no significant differences in median OS or PFS across subgroups defined by ER/PR expression, Ki67 expression levels, and lymph node metastasis (P > 0.05). The gene discussed is ESR1; the disease is metastatic malignant neoplasm in the lymph nodes.